Education
About Us
Working with TipRanks
Follow Us
Regeneron (DE:RGO)
XETRA:RGO
RGO Stock Chart & Stats
€651.00
-€7.80(-1.10%)
At close: 4:00 PM EST
€651.00
-€7.80(-1.10%)
Day’s Range― - ―
52-Week Range€420.00 - €702.60
Previous CloseN/A
Volume0.00
Average Volume (3M)63.00
Market Cap
€69.76B
Enterprise Value€78.54B
Total Cash (Recent Filing)€8.61B
Total Debt (Recent Filing)€2.71B
Price to Earnings (P/E)17.9
Beta0.32
Next Earnings
Apr 30, 2026EPS Estimate
7.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.94
Shares Outstanding103,902,660
10 Day Avg. Volume51
30 Day Avg. Volume63
Financial Highlights & Ratios
PEG Ratio3.38
Price to Book (P/B)2.58
Price to Sales (P/S)5.63
P/FCF Ratio19.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€752.72Price Target Upside15.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering24
EPS Forecast (FY)38.99
Revenue Forecast (FY)€13.52B
Bulls Say, Bears Say
Bulls Say
Core Franchise StrengthAnalyst notes Dupixent's long safety record and ongoing label expansions support sustained sales growth and create a high barrier to competitor displacement.
Oncology Clinical CatalystAnalyst expects a positive Phase 3 result for the fianlimab plus Libtayo combination in first-line melanoma, which could differentiate the company from rivals and drive meaningful market share gains if confirmed.
Ophthalmology Lifecycle ManagementAnalyst points to strong early uptake of the higher-dose Eylea formulation and indicates that approval of a pre-filled syringe plus label enhancements and patient support programs would accelerate adoption and stabilize the eye franchise.
Bears Say
Biosimilar CompetitionAnalyst warns that biosimilar entry and dose mix shifts are eroding standard-dose Eylea sales and could materially reduce revenue from the eye franchise.
Clinical Development RiskAnalyst cautions that encouraging early-stage results require randomized Phase 3 confirmation and that late-stage failures remain a significant risk to pipeline value.
Profitability PressureAnalyst highlights guidance showing lower gross margins from product mix changes and transient investments, indicating pressure on overall profitability.
Regeneron News
RGO FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was €420.00 and its highest was €702.60 in the past 12 months.
What is Regeneron’s market cap?
Regeneron’s market cap is €69.76B.
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Apr 30, 2026 which is in 52 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Jan 30, 2026. The company reported €9.937 earnings per share for the quarter, beating the consensus estimate of €9.325 by €0.611.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron does not currently pay dividends.
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is 7.93.
How many shares outstanding does Regeneron have?
Regeneron has 103,902,660 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of €9.937 in its last earnings report, beating expectations of €9.325. Following the earnings report the stock price went down -0.865%.
Which hedge fund is a major shareholder of Regeneron?
Currently, no hedge funds are holding shares in DE:RGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Regeneron Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€752.72 (15.63% Upside)
€752.72 (15.63% Upside)
Blogger Sentiment
Bullish
DE:RGO Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 89%
Bearish news 11%
Bearish news 11%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.38%
12-Months-Change
Fundamentals
Return on Equity
14.87%
Trailing 12-Months
Asset Growth
7.15%
Trailing 12-Months
Company Description
Regeneron
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
RGO Company Deck
RGO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial commercial strength (notably Dupixent, EYLEA HD, Libtayo), solid financials, strong cash generation, aggressive shareholder returns, and a deep pipeline with multiple near‑term readouts and regulatory objectives. Headwinds were acknowledged — including EYLEA 2 mg biosimilar pressure, short‑term inventory timing, manufacturing/regulatory risk for the prefilled syringe, patient affordability challenges, and higher R&D and SG&A investments. On balance, the positives — large, high‑growth franchises, robust cash flow, and multiple potentially transformative clinical programs — materially outweigh the near‑term challenges and risks discussed.View all DE:RGO earnings summariesRGO Revenue Breakdown
43.99% Net product sales
51.11% Collaboration revenue
4.90% Other revenue
RGO Stock 12 Month Forecast
Average Price Target
€752.72
▲(15.63% Upside)
Technical Analysis
Options Prices
Currently, No data available
---